Aviva PLC Grows Position in Amgen Inc. $AMGN

Aviva PLC grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 5.5% in the fourth quarter, HoldingsChannel.com reports. The fund owned 450,901 shares of the medical research company’s stock after purchasing an additional 23,465 shares during the period. Aviva PLC’s holdings in Amgen were worth $147,584,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Mosley Wealth Management bought a new position in shares of Amgen in the fourth quarter worth approximately $419,000. Founders Financial Alliance LLC increased its position in shares of Amgen by 32.7% in the fourth quarter. Founders Financial Alliance LLC now owns 2,043 shares of the medical research company’s stock worth $669,000 after purchasing an additional 504 shares during the last quarter. Resurgent Financial Advisors LLC increased its position in shares of Amgen by 16.4% in the fourth quarter. Resurgent Financial Advisors LLC now owns 2,724 shares of the medical research company’s stock worth $892,000 after purchasing an additional 384 shares during the last quarter. Sustainable Insight Capital Management LLC bought a new position in shares of Amgen in the fourth quarter worth approximately $274,000. Finally, Investment Research Partners LLC increased its position in shares of Amgen by 2.1% in the fourth quarter. Investment Research Partners LLC now owns 3,708 shares of the medical research company’s stock worth $1,214,000 after purchasing an additional 75 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

NASDAQ:AMGN opened at $354.06 on Friday. The business has a 50 day moving average of $340.94 and a 200 day moving average of $345.65. The company has a market capitalization of $191.09 billion, a price-to-earnings ratio of 24.64, a PEG ratio of 3.39 and a beta of 0.42. Amgen Inc. has a 1-year low of $267.83 and a 1-year high of $391.29. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same quarter in the previous year, the company posted $4.90 EPS. Amgen’s quarterly revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, sell-side analysts predict that Amgen Inc. will post 22.38 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares in the company, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.85% of the company’s stock.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen presented new Phase 3 VESALIUS-CV data showing Repatha significantly reduced cardiovascular risk in high-risk diabetes patients, strengthening the case for its cardio-metabolic franchise. Here is Why Amgen (AMGN) is One of the Top Large Cap Value Stocks to Buy Now
• Positive Sentiment: Investor coverage remains bullish, with articles highlighting Amgen as a potential value stock and pointing to attractive valuation metrics versus expected earnings growth. Is Amgen Inc. (AMGN) A Good Stock To Buy Now?
• Positive Sentiment: Amgen updated investors on its Phase 3 MARITIME-SWITCH trial, which targets GLP-1 switchers in obesity, supporting its strategy to win share in a rapidly expanding market. Amgen’s MARITIME-SWITCH Trial Targets GLP-1 Switchers in the Growing Obesity Drug Market
• Neutral Sentiment: Several market commentary pieces discussed Amgen as a large-cap value or healthcare exposure idea, but these are mostly sentiment-driven rather than immediate fundamentals. Healthcare ETFs: From Broad Exposure to Big Breakthroughs
• Negative Sentiment: Recent trading-day coverage noted Amgen underperformed the broader market, suggesting some short-term profit-taking or volatility even as the longer-term story improves. Amgen Inc. stock underperforms Wednesday when compared to competitors

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Piper Sandler decreased their price objective on shares of Amgen from $432.00 to $427.00 and set an “overweight” rating on the stock in a research report on Thursday, May 14th. Wells Fargo & Company boosted their target price on Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a research report on Thursday, March 19th. Leerink Partners restated a “market perform” rating and issued a $355.00 target price on shares of Amgen in a research report on Thursday, March 5th. Cantor Fitzgerald restated a “neutral” rating and issued a $350.00 target price on shares of Amgen in a research report on Wednesday, April 8th. Finally, Barclays initiated coverage on Amgen in a research report on Friday, February 20th. They issued an “equal weight” rating and a $350.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $354.12.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.